MedTrace Logo

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

NCT06795204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects

Conditions

  • Anesthesia; Adverse Effect
  • Cardiac Arrhythmia

Interventions

DRUG

HSK3486

Study Drug

DRUG

Moxifloxacin Hydrochloride

Positive Control

DRUG

Placebo

Negative Control

Sponsors & Collaborators

  • Haisco-USA Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-09
Primary Completion
2024-05-19
Completion
2024-11-26
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06795204 on ClinicalTrials.gov